Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 8/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.37 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10199328 | 0.95 | XIAP (0.42) | XIAPTAS1R3TAS1R1TSHRCASP1 | |
| SCHEMBL10200433 | 0.93 | CASP1 (0.41) | XIAPTAS1R3TAS1R1TSHRCASP1 | |
| SCHEMBL10200292 | 0.93 | XIAP (0.40) | XIAPTAS1R3TAS1R1TSHRCASP1 | |
| SCHEMBL10249838 | 0.88 | XIAP (0.46) | XIAPCYP3A4 | |
| SCHEMBL10249823 | 0.88 | CASP1 (0.47) | XIAPCASP1CYP3A4 | |
| SCHEMBL10201820 | 0.87 | XIAP (0.39) | XIAPTAS1R3TAS1R1TSHRCASP1 | |
| SCHEMBL10200505 | 0.87 | KDM4E (0.42) | XIAPTSHRCASP1KDM4EALDH1A1 | |
| SCHEMBL13139787 | 0.87 | KDM4E (0.42) | XIAPTSHRCASP1KDM4EALDH1A1 | |
| SCHEMBL13139782 | 0.87 | MAPT (0.40) | XIAPTSHRKDM4EALDH1A1 | |
| SCHEMBL10200507 | 0.87 | MAPT (0.40) | XIAPTSHRKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119631-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | XIAP 257/4885TAS1R3 3754/4885TAS1R1 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.